UW Department of Pharmacy Faculty Meeting Agenda...Steve White opens, welcoming everyone to the...

UW Department of Pharmacy Faculty Meeting Agenda Monday, March 16th, 2020

09:00 to 10:30 am Venue: Zoom Conference URL: https://washington.zoom.us/j/534540943

Zoom Phone Number: +1 669 900 6833

Meeting ID: 534-540-943

Topic/ Business Presenter Appro.

time Page

1. Welcome and Announcements • Space Committee Update • Update on on-going Faculty Searches

White 10 min

2. Approval of Minutes (October 2019 meeting) [Vote requested]

White 2 min

3. Faculty Appointments [Vote Requested] • CHOICE Affiliate appointments

Devine/Carlson/Veenstra

15 min

4. EE Update Danielson 10min

5. Curriculum Committee, GOLD and PURPLE Curriculum Updates • Update on remote teaching, and wrapping up the quarter

Chan 40 min

6. 5 and 10 Presentation

Marcum 10 min

7. Other Business

https://washington.zoom.us/j/534540943

DOP Faculty Meeting Minutes February 10, 2020

1

DOP Faculty Meeting 9:00 am H371 Meeting called by: H. Steve White Notes by: Meghan Turner

Attendees

Present: R. Allen, M. Barker-Haliski, D. Barthold, D. Black, J. Carlson, L-N Chan, J. Chang, L. Cirrincione, J. Danielson, K. Dawson, B. Devine, J. Do, D. Downing, A. Ellsworth, S. Gray, R. Hansen, T. Hazlet, M. Hebert, Z. Marcum, L-A Mike, T. O’Sullivan, P. Odegard, D. Veenstra, B. Werth, H.S. White, S. Wu, C. Yeung Absent: J. Bacci, A. Bansal, A. Basu, R. Firebaugh, L. Garrison, A. Goo, J. Plein, S. Somani, S. Stergachis, S. Sullivan, J. Wilson Norton Staff Present: S. Ahmed, M. Gano, P. Hedtke, M. Kimura, K. Luetjen, M. Turner

1. Welcome/ Acknowledgements/ Announcements

10 min White

Discussion:

Welcome and Announcements (White): Steve White opens, welcoming everyone to the first faculty meeting of 2020. Beginning with announcements, Steve shares that an Ad Hoc Space Committee has been formed by the Dean’s Office to discuss new F-Wing space that has been assigned to the SOP. Each Chair has been charged with meeting with individuals throughout the Departments to get a feel for what is needed. While Steve cannot meet with everyone, he assures the faculty that he is carefully considering a wide variety of options as the Committee deliberates. However, Steve notes that this is not an opportunity for everyone to expand. Instead, this is an opportunity to discuss current space utilization and needs. Steve acknowledges Grants Manager Karen Luetjen, who’s last day in the Department will be February 21st. Karen has accepted an exciting new opportunity in the Office of Research. Steve recognizes Karen’s dedication and hard work during her 3-year tenure with the Department, noting that during this time the department enjoyed a nearly 50% award rate, totaling an estimated $53 million. Steve states that this speaks not only to the productivity and passion of the faculty for scholarship efforts, but also the significant efforts on Karen’s behalf. Karen will be missed.

2. Approval of Minutes 2 minutes H. Steve White

Discussion

The DRAFT Meeting Minutes of the December 2019 faculty meeting were presented to all prior to the meeting for review.

Motion to Approve:

First: Karan Dawson Second: Don Downing

Vote

Eligible: 38 Yes: 27 No: 0 Abstain: 0 Absent for Vote: 11 Note: Votes included from those present at the meeting and via email response.


2

Action and by: The minutes will be noted as FINAL and posted to the intranet.

3. Course Approvals

5 min Hansen/Chan

Discussion Pharm 540 – Systematic Reviews and Meta-Analysis (Hansen):

Motion

First: Mary Hebert Second: Beth Devine

Vote


4. Kedzierski Emeritus Appointment

3 min. White

Discussion

In November 2019, a vote was taken regarding Micki Kedzierski’s nomination for appointment as Clinical Professor Emeritus. The vote unanimously passed. However, Micki’s appointment could not be considered by AHR until after her official retirement. As a procedural issue, Steve White inquires if the Faculty feels that there is a need to strike the original vote, and take a new one. The Faculty unanimously felt that a vote could instead be taken to re-affirm Micki’s previous nomination and vote by the faculty.

Motion

First: Leigh Ann Mike Second: Mary Hebert

Vote


5. Curriculum Updates

15 min Open Discussion/Chan

Discussion

Gold and Purple Curriculum: Lingtak Chan shares updates regarding the Gold and Purple Curricula, beginning by thanking the faculty for ensuring there were an adequate number of electives offered. Focusing in on the in-progress Remediation Plan, Lingtak shares that the plan continues to be revised and updated. Also in the works is the new Course Evaluation Form, which was highlighted with the purple curriculum. The Course Evaluation task force is expected to reconvene in the near future to review feedback from the students and end users. There will be an updated form for the Spring Quarter, which will continue to be expanded. Lingtak shares that the Curriculum Committee is working to ensure there is an appropriate number of electives offered in the Spring Quarter. Focusing on specific courses, Lingtak shares that the former (Gold Curriculum) Pharm 515 – Pharmacy and Law course has now been dispersed throughout


3

multiple courses in the new (Purple) curriculum. Don Downing has agreed to help guide and oversee the content and integration into the Purple curriculum. Lingtak shares that there is an on-going realignment of elective courses due to begin in Autumn 2020 Quarter. The Discovery Series is set to go with three departments set to host. However, the Longitudinal Project series has been placed on hold indefinitely due to staffing concerns. Lingtak stresses that this is not gone – just on hold. Students may still enroll as an independent study if they’d like to proceed. Terri O’Sullivan is working with the APPE Guidance Committee, preparing and discussing the new APPE course applications. Lingtak states this is a very broad topic, that will take time to approve. Lingtak acknowledges faculty members who are double teaching this quarter, and those who are experiencing classroom challenges, including Gail Anderson, Brian Werth, Jennifer Wilson Norton.

6. Experiential Education/ Advising and Student Success

30 min Danielson/Brusletten

Discussion

Jennifer Danielson welcomes the Experiential Education staff to the meeting and shares that Amy Wassell will be introducing the new Experiential Education staff to the Department. Amy introduces Cristina Galicia, Associate Director of Experiential Education, Introductory Practice, and Kyle Wunderlin, Associate Director of Experiential Education, Intermediate Practice, and discusses their roles within the EE team. Andrew Brusletten introduces Caitlin Blomquist, M.Ed., the School of Pharmacy’s new Director for Advising and Student Success. Caitlin joins the SOP from the Evan’s School where she was the Associate Director for Student Services. Caitlin has over 6 years of experience in Student Support. Continuing, Andrew presents the newly implemented, still in-progress Advising Model for the School. This new approach is team based and wholistic in nature, with individual advising assignments. Additionally, Andrew presents new scheduling tools, the new early detection process, and discusses the mechanism for developing academic plans.

7. Department Business

20 min


4

Discussion

Teleconferencing System Update/Presentation - (Joselyn/Turner): James Josleyn and Meghan Turner share a brief update regarding the recent upgrades to the DOP conference room teleconferencing system. Please feel free to connect with James or Meghan regarding any questions regarding its use. Faculty Recruitment Updates: Three candidates have interviewed in the past two weeks for the position of Faculty Fellow. Steve acknowledges everyone, thanking them for their time to meet with the candidates, and requests candidate feedback be sent to Peggy Odegard and Lingtak Chan no later than tomorrow. CHOICE has initiated a search for an Assistant Professor with Health Economy training and expertise. The first candidate will be visiting the DOP on the 20th February. Steve encourages everyone to try and attend the scheduled seminar.

8. 5 and 10 Presentation 10 min White Discussion

Melissa Barker-Haliski presents her research on Epilepsy in an Aging Population.

9. Research and Grants 3 minutes K. Luetjen Discussion

Please see the attached spreadsheets regarding requested and awarded grants.

Meeting is Adjourned.

Box 357630 1959 NE Pacific St. Suite H375 Seattle, WA 98195-7630

206.616.1383 sop.washington.edu/choice

Affiliate Faculty Appointment Nomination:

Zsolt Hepp, PharmD, MS

For nomination at the rank: Affiliate Assistant Professor

CONTENTS

CURRICULUM VITAE………………………………………………………………..……….…............................. 4

NOMINATION LETTER FROM DR. JOSH CARLSON.. ……………………...........…………................ 3

CHOICE ADJUNCT/AFFILIATE FACULTY CRITERIA………………….........………...............……….. 10

1

February 18, 2020

Faculty, Department of Pharmacy

University of Washington

RE: Affiliate Faculty nomination for Zsolt Hepp

Dear Colleagues,

It is my pleasure to nominate Zsolt Hepp, PharmD, MS, for an Affiliate Assistant Professor appointment

with the Department of Pharmacy. Dr. Hepp is Director, Global HEOR at Seattle Genetics and the mentor

and director of the health economics and outcomes research (HEOR) post-PharmD MS fellowship program

our Department has with Seattle Genetics. The fellows in this program complete one year of training,

including an MS degree, with us, followed by a year on-site with Seattle Genetics.

He received his PharmD from University of Washington School of Pharmacy and also obtained his MS in

Pharmaceutical Sciences from the University of Washington, School of Pharmacy. He has worked in

industry for the past 7 years, and currently holds a senior position directing 2 employees. He has also

authored 18 manuscripts and 21 conference presentations including 6 podium presentations.

Dr. Hepp, has provided strong mentorship to our current Seattle Genetic fellow, Phoebe Wright, and helped

recruit an excellent candidate for next year. Dr. Hepp has also developed an internship program in HEOR at

Seattle Genetics, in which our students have participated and will continue to do so. This represents a vital

link for our program to a successful local biopharmaceutical company. He is also an active SoP alumni.

His plan moving forward will be to provide occasional lectures and presentations in our classes as well

continued mentorship to our Seattle Genetics fellows and other students.

Dr. Hepp is accomplished and well respected in the HEOR community and would be a great representative

of the University of Washington. Dr. Hepp meets the Affiliate Faculty criteria established for The CHOICE

Institute by demonstrating ongoing engagement through student mentorship. I highly recommend Dr. Hepp

for an Affiliate Faculty position, and propose he be appointed at an Assistant Professor level. I look forward

to discussing and would be happy to answer any questions.

Thank you for considering this request.

Sincerely,

Josh J. Carlson, MPH, PhD

Associate Professor

The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute

School of Pharmacy

University of Washington

Email: [email protected]

Tele: 206.543.964

of 3

ZSOLT HEPP, PHARMD, MS 805.490.0253, [email protected]

Education DOCTOR OF PHARMACY University of Washington

MS, PHARMACEUTICAL OUTCOMES RESEARCH AND POLICY PROGRAM University of Washington

BS, AVIATION BUSINESS MANAGEMENT University of Oklahoma

Professional Experience SEATTLE GENETICS INC, Bothell, WA Director, Global Health Economics and Outcomes Research Apr 2018 - Present Global product lead for a very exciting new oncology therapy that is a novel antibody drug conjugate recently approved for late stage bladder cancer patients. My role is primarily the development and execution of a broad strategy that spans the current launch as well as a number of pipeline investigations of the product in various other cancers with the aim to develop a value evidence package that can support the product’s submission to multiple countries with multiple different indications. Strong collaboration with the medical, clinical, regulatory, and commercial organizations to ensure the HEOR strategy and the studies conducted therein serve useful purpose in delivering insights for internal decision making as well as provide key value messages for our products. In addition to my role in HEOR I am also the director of the Seattle Genetics fellowship in collaboration with University of Washington mentoring two students over the two-year program. ABBVIE INC, North Chicago, IL Associate Director, US Health Economics and Outcomes Research Nov 2017 – Apr 2018 In my last role at AbbVie I led the development of health outcomes strategy for Humira for two of its gastroenterology indications in inflammatory bowel disease (IBD) as well as support the robust pipeline of IBD treatments in the AbbVie immunology portfolio. I lead a number of high visibility high profile projects such as the development of a care pathway for IBD, a project that spans multiple stakeholders including payers, national physician societies, and many key opinion leaders. Additionally I designed and implemented US-specific health outcomes research to support continued reimbursement of Humira, the highest selling branded drug in the world, in an ever-growing competitive market.

Associate Director, Global Health Economics and Outcomes Research Feb 2016 – Nov 2017 I led the development of health outcomes strategy for two marketed products in endocrinology: Synthroid and AndroGel, as well as provided additional support for the business development teams in virology and hepatology. I designed and implemented health outcomes research to demonstrate overall product value to support market access and reimbursement by generating the following types of evidence:

Observational studies such as retrospective claims analyses and prospective non-interventional studies to demonstrate real-world effectiveness of Synthroid and AndroGel in the appropriate populations

of 3

Epidemiology and burden of illness studies using cross-sectional surveys and claims analyses to demonstrate need for better management of hypothyroidism and hypogonadism

Early economic modeling to demonstrate cost-effectiveness of new interventions and to support value based pricing for use in forecasting of business development opportunities in hepatic diseases

Support of patient-reported outcomes (PRO) strategy by validating PRO instruments and incorporation of PROs into clinical trial design for AndroGel and early assessments for hepatology pipeline

In addition to the core functions, in both my roles at AbbVie I was/am also responsible for: Engaging external stakeholders and key opinion leaders to ensure projects are generating useful and

important evidence for patients, clinicians, and payers and working with these stakeholders to generate useful internal or external materials for pull-through of that research

Managing and/or writing abstracts, posters, and manuscripts Mentoring pharmacy students, interns, and fellows through teaching and direct supervision of projects Planning and managing of projects and their associated budgets

ALLERGAN PLC, Irvine, CA Manager, Global Health Economics and Outcomes Research Oct 2013 – Feb 2016 As the head of urology within GHEOR, I led the development of health outcomes strategy for all pipeline and currently marketed products within this therapeutic area. During my time at Allergan, I completed a number of highly impactful real-world effectiveness, comparative effectiveness, and cost-effectiveness studies that helped demonstrate overall product value to support global market access and reimbursement for BOTOX® for chronic migraine and overactive bladder. In addition, I supported three urology pipeline assets in various stages of development for which I was a responsible for developing a robust evidence package to prepare for launch. This included developing value story for each asset, running multiple studies to establish the burden of illness for each disease state, creating and executing extensive PRO strategies including developing disease specific PROs, and building early cost effectiveness models to inform pricing and clinical trial design. I worked closely with clinical, medical affairs, regulatory/labeling, commercial, and marketing teams to provide HEOR input at all stages of product development and to ensure pull through of all relevant research for internal and external use by stakeholders. In addition to the research, I was also in charge of managing TA budget, contracting, and all publications related to my research.

UNIVERSITY OF WASHINGTON, Seattle, WA Health Outcomes Research Assistant Apr 2011 – Jun 2014

Assisted in day-to-day research projects through systematic literature searches, medical writing and editing, and technical model development

Designed and implemented a pharmacoeconomic model to evaluate the cost-effectiveness of replacing paper-prescribing with Computerized Physician Order Entry System (CPOE) in an ambulatory care setting

Post-Doctoral Research Fellow Jun 2012 – Oct 2013 Received didactic training in statistics and epidemiology as well as experiential training in the following disciplines along with the subsequent research projects listed below:

Economic Evaluation in Health and Medicine: Cost-Effectiveness of OnabotulinumtoxinA (BTX) Injection versus Nitroglycerin (NTG) Ointment for the Treatment of Chronic Anal Fissures

Health Outcomes: Utility Score Estimates of Patient with Chronic Anal Fissures: Systematic Review of Quality of Life Instruments and SF-36 Mapping Exercise

Methods in Pharmaceutical Policy Analysis: Overview of the Current Policies on Drug Importation and a Policy Proposal to Reduce Illegitimate Internet Drug Sales

Thesis: Adherence to Oral Migraine Prophylaxis Medications in Patients with Chronic Migraine

of 3

FORMULARY RESOURCES, Seattle, WA Consultant Mar 2011 – Aug 2013

Reviewed new medications and wrote/presented full monographs for pharmacy and therapeutics committee meetings for regional health plan

Provided medical writing support for the development of AMCP dossiers for a variety of pharmaceutical companies

WALGREENS, Seattle, WA Pharmacist Sept 2012 – Sept 2015

Provided the highest level of pharmaceutical care for patients through disease management and general health consulting, while maintaining efficiency and expediency

Dispensed medications accurately and collaborated with providers to ensure that prescriptions are fulfilling therapy goals for individual patients

Established positive relationships with the community by providing a variety of services including over-the-counter medication advice, medication therapy management, and comprehensive health testing services including immunizations

Additional experience at Walgreens as an Assistant Store Manager (2005-2006) and Pharmacy Technician/Intern (2006-2012) Professional Affiliations / Awards / Certificates AbbVie Performance Awards:

• 2017 AndroGel Integrated Brand Team Leader Award • Recipient of Over 10 Excellence Awards for Performance, Collaboration and Leadership

ISPOR: International Society of Pharmacoeconomics and Outcomes Research

• Best New Investigator Poster Presentation, 2013 ISPOR Conference • ISPOR Short Course Certificates: Introduction to Conjoint Analysis, Advanced Patient Reported

Outcomes, Network Meta-Analysis, Advanced Decision Modeling, Propensity Score in Observational Research

AMCP: Academy of Managed Care Pharmacy • Board Member - University of Washington Chapter (2010 - 2011) • AMCP/FMCP National P&T Competition, 2nd Place (2010)

NCPA: National Community Pharmacy Association • National NCPA Pruitt-Schutte Student Business Plan Competition, 1st Place (2009)

Published Articles Lage MJ, Vora J, Hepp Z, Espaillat R. Levothyroxine Treatment of Pregnant Women with Hypothyroidism: Retrospective Analysis of a US Claims Database. Adv Ther. 2020 Feb;37(2):933-945. Hepp Z, Wyne K, Manthena S, Wang S, Gossain V. Adherence to Thyroid Hormone Replacement Therapy: A Retrospective, Claims Database Analysis. Curr Med Res Opin. 2018 Sep; 34(9):1673-1678.

of 3

Hepp Z, Lage M, Espaillat R, Gossain V. Economic and Clinical Benefits of Adherence to Levothyroxine in Patients with Hypothyroidism in the US. J Med Econ. 2018 Sep; 21(9):912-919. Khandelwal N, Johns B, Hepp Z, Castelli-Haley J. The economic impact of switching from Synthroid for the treatment of hypothyroidism. J Med Econ. 2018 May; 21(5):518-524. Hepp Z, Kim G, Lenhart G, Johnson BH. Absenteeism and Indirect Economic Burden Associated With Primary and Secondary Hypogonadism: A Retrospective Matched Cohort Analysis of Employed, Commercially Insured Patients in the U.S. J Occup Environ Med. 2018 Aug; 60(8):724-731. Gelhorn HL, Roberts LJ, Khandelwal N, Revicki DA, DeRogatis LR, Dobs A, Hepp Z, Miller MG. Psychometric Evaluation of the Hypogonadism Impact of Symptoms Questionnaire Short Form (HIS-Q-SF). J Sex Med. 2017 Aug; 14(8):1046-1058 Drake M, Nitti V, Ginsberg D, Brucker B, Hepp Z, McCool R, Glanville J, Fleetwood K, James D, Chapple C. A Comparative Assessment of Efficacy of OnabotulinumtoxinA and Oral Therapies (Anticholinergics and Mirabegron) for Overactive Bladder: A Mixed Treatment Comparison. BJU Int. 2017 Nov; 120(5):611-622. Keyloun K, Hansen R, Hepp Z, Gillard P, Thase M, Devine EB. Adherence and Persistence across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis among Insured US Patients with Major Depressive Disorder (MDD). CNS Drugs. 2017 May; 31(5):421-432. Tung A, Hepp Z, Bansal A, Devine EB. Characterizing Healthcare Utilization, Direct Costs, and Comorbidities Associated with Interstitial Cystitis: A Retrospective Claims Analysis. J Manag Care Spec Pharm. 2017 Apr;23(4):474-482. Hepp Z, Dodick D, Varon S, Chia J, Matthew N, Gillard P, Hansen R, Devine EB. Persistence and Switching Patterns of Oral Migraine Prophylactic Medications Among Patients with Chronic Migraine. Cephalalgia. 2017 Apr;37(5):470-485.

Ruff L, Bagshaw E, Aracil J, Velard ME, Pardhanani G, Hepp Z. Economic impact of onabotulinumtoxinA for overactive bladder with urinary incontinence in Europe. J Med Econ. 2016 Jul 15:1-9. Epub 2016 Jul 15. Hepp Z, Rosen NL, Gillard PG, Varon SF, Mathew N, Dodick DW. Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: Retrospective analysis of a US-based insurance claims database. Cephalalgia. 2016 Aug;36(9):862-74. Chartier-Kastler E, Rovner E, Hepp Z, Khalaf KM, Ni Q, and Chancellor M. Patient-Reported Goal Achievement Following OnabotulinumtoxinA Treatment in Patients With Neurogenic Detrusor Overactivity. Neurourol Urodyn. 2016 Jun;35(5):595-600. Hepp Z, David DW, Gillard P, Varon SF, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015 May; 35 (6):478-88. Forrester S, Hepp Z, Roth J, Wirtz H, Devine EB. Cost-effectiveness of a computerized provider order entry system in improving medication safety in ambulatory care. Value Health. 2014 Jun; 17 (4):340-9 Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm. 2014 Jan; 20(1): 22-33.

of 3

Submitted Manuscripts Kera M, Manthena S, Hepp Z. Impact of a Patient Support Program for AndroGel 1.62% (Topical Testosterone Gel) On Adherence and Healthcare Costs Among Males With Primary Or Secondary Hypogonadism. Journal of Sexual Medicine, Submitted Aug 2018 Podium Presentations Hepp Z, Manthena S, Kera M. Impact of a Patient Support Program for AndroGel 1.62% (Topical Testosterone Gel) On Adherence Among Males With Primary Or Secondary Hypogonadism. 18th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America. October 26-29, 2017. San Antonio, TX. Hepp Z, Lage MJ, Espaillat R. The Direct and Indirect Economic Burden of Hypothyroidism in the United States: A Retrospective Claims Database Study. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting, May 20-24, 2017. Boston MA. Ginsberg D, Drake M, Chapple C, McCool R, Glanville J, Fleetwood K, James D, Hepp Z, Nitti V. Network Meta-Analysis To Assess The Treatment Effect Of OnabotulinumtoxinA, Mirabegron and Anticholinergics Versus Placebo For Overactive Bladder. 2016 American Urological Association North Central Section Annual Meeting, September 7-10, 2016. Chicago, Illinois. Hepp Z, Rosen N, Varon SF, Gillard P, Mathew N, David DW. The Real-World Impact of OnabotulinumtoxinA on Headache-Related ER Visits and Hospitalizations in the Management of Chronic Migraine. American Academy of Neurology 67th Annual Meeting, April 22nd, 2015. Washington DC. [S23.004] Freemantle N, Khalaf K, Hepp Z, Ni Q, Fleetwood K, Stanisic S, Lister J, Loveman C, Drake M. Cost-Effectiveness of OnabotulinumtoxinA vs. Mirabegron for the Treatment of Overactive Bladder from the UK National Health Perspective. The 30th Anniversary European Association of Urology Conference, March 20-25, 2015. Madrid, Spain. [151] Hepp Z, David DW, Gillard P, Varon SF, Hansen RN, Devine EB. Adherence to oral migraine preventive medications among patients with chronic migraine: analysis of a large US health insurance claims database. American Academy of Neurology 66th Annual Meeting, April 26-30, 2014. Philadelphia, PA. [S41.009] Posters Hepp Z, Shah SN, Tan K, Balakrishna S. Real-world outcomes in patients with locally advanced or metastatic urothelial carcinoma receiving taxane monotherapy following platinum and anti-PD-1/L1 therapy. ASCO GU 2020, February 24th, 2020. San Francisco, CA. Abstract 458, Poster G3. Hepp Z, Morgans A, Shah SN, Shah A, Petrilla A, Small M, Sonpavde G. Real world burden of illness and unmet need in locally advanced or metastatic urothelial carcinoma following discontinuation of PD-1/PD-L1 inhibitor therapy: a Medicare claims database analysis. AMCP Nexus 2019, October 30, 2019. National Harbor, Maryland. Poster C27. *Gold Ribbon Award Winner* McGregor BA, O’Donnell PH, Balar A, Petrylak D, Rosenberg JE, Yu EY; Quinn DI, Shah SN, Pinelli J, Hepp Z, Glasky MD. Quality of Life of Metastatic Urothelial Cancer (mUC) Patients Treated with Enfortumab Vedotin (EV) Following Platinum-containing Chemotherapy and a Checkpoint Inhibitor (CPI): Data from EV-201 Cohort 1. ESMO 2019 Congress, September 27-October 1, 2019. Barcelona, Spain. Poster 921P. Shah MV, McGovern A, Hepp Z. Targeted Literature Review of the Burden of Illness in Urothelial Carcinoma. ISPOR-EU 2018, 10–14 November 2018, Barcelona, Spain. Poster PCN108

of 3

Shah M, Devine J, Wang S, Hepp Z, Shah SN. Patient-Reported Symptoms and Impacts of Locally Advanced or Metastatic Urothelial Cancer After Chemotherapy Followed by a PD-1/PD-L1 Checkpoint Inhibitor. ASCO GU February 15, 2019. San Francisco, CA. Poster F15 Chiorean M, Afzali A, Cross R, Zhou Z, Macaulay D, Ganguli A, Hepp Z, Wang A. Economic Impact of Switching from Anti-TNF Therapy to Adalimumab, Infliximab or other Anti-TNF Compared with Switching from Anti-TNF Therapy to Vedolizumab. Crohn’s and Colitis Congress, January 18 – 20, 2018, Las Vegas, Nevada. Poster #143 Hepp Z, Wang S, Espaillat R. Comparative Effectiveness of Synthroid® vs Generic Levothyroxine on TSH Lab Outcomes: A Retrospective Claims Database Analysis. American Association of Clinical Endocrinologists (AACE) 26th Annual Scientific and Clinical Congress, May 3–7, 2017, Austin, TX, USA. Poster #1063 Lage M, Espaillat R, Vora J, Hepp Z. The Treatment of Hypothyroidism among Pregnant Women: A Retrospective Analysis. American College of Obstetricians and Gynecologists 2018 Annual Clinical and Scientific Meeting, April 27-30, 2018 Austin, TX, USA. [13M] Hepp Z, Wang S, Manthena S. Adherence to Thyroid Hormone Replacement Therapy. American Association of Clinical Endocrinologists (AACE) 26th Annual Scientific and Clinical Congress, May 3–7, 2017, Austin, TX, USA Poster #1066 Hepp Z, Yehoshua A, Gultyaev D, Lister J, Boer R. Cost-Effectiveness of OnabotulinumtoxinA Vs. PTNS And SNS for the Treatment Of Overactive Bladder From the US Payer Perspective. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting, May 21–25, 2016, Washington, DC. [PUK11] Tung A, Hepp Z, Bansal A, Devine EB. Characterizing Healthcare Utilization, Direct Costs, and Comorbidities Associated with Interstitial Cystitis: A Retrospective Claims Analysis. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting, May 21–25, 2016, Washington, DC. [PUK10] Hepp Z, David DW, Gillard P, Varon SF, Chia J, Mathew N, Hansen RN, Devine EB. Persistence and Switching Characteristics Among a Chronic Migraine Patient Population: A Retrospective Claims Analysis. Diamond Clinic Headache Update Conference. June 17-20, 2014. Orlando FL. Also presented at the European Headache and Migraine Trust International Congress. September 18-21, 2014. Copenhagen, Denmark. Hepp Z, David DW, Gillard P, Varon SF, Hansen RN, Devine EB. Adherence to oral migraine preventive medications among patients with chronic migraine: analysis of a large US health insurance claims database. Academy of Managed Care Pharmacy 26th Annual Meeting and Expo. April 2-4, 2014. Tampa, FL. [G13] Hepp Z, Forrester S, Roth J, Wirtz H, Devine EB. Cost effectiveness of a computerized prescriber order entry system in improving medication safety: a case study in ambulatory care. International Society of Pharmacoeconomics and Outcomes Research 18th Annual International Meeting, May 18-22, 2013, New Orleans, LA. Bloudek LM, Hepp Z, Chia J, Varon SF. Claims-based analysis of the impact of adherence to oral migraine prophylaxis in a newly diagnosed chronic migraine population. American Academy of Neurology 64rd Annual Meeting, April 21- 28, 2012. New Orleans, LA [PO4.238].

Last Revised: May 2019

Criteria for becoming Adjunct or Affiliate Faculty with The CHOICE Institute

Faculty interested in contributing to The CHOICE Institute mission of generating knowledge to

improve individual and population health through transformative learning, research, and

dissemination about the effectiveness, safety, and value of medical products, services, and policies

as an Adjunct or an Affiliate faculty must demonstrate the following criteria.

Adjunct Faculty

The CHOICE Institute will follow the Guidelines for Adjunct Faculty as described in the UW faculty

code: http://www.washington.edu/admin/rules/policies/FCG/FCCH24.html

This document provides additional guidance and customized procedures.

Guidelines for annual appointment – Must meet at least one of the following criteria over any

two successive academic years:

1. Teaching: Teach multiple lectures in one or more of the courses offered within The Institute.

2. Mentorship: Serve as mentor or dissertation/thesis committee member for graduate

students within The Institute.

3. Collaboration: Engage in substantial research collaborations with the core DOP faculty of The

Institute.

4. Leadership: Participate in student-led outreach activities, public lectures, and symposia, or

other community-engagement with The Institute.

Affiliate Faculty

The CHOICE Institute will follow the Department of Pharmacy Guidelines for Affiliate Faculty as

described here: https://sop.washington.edu/about/office-of-the-dean/clinical-affiliate-

faculty/guidelines/

These guidelines are consistent with the UW faculty code:

http://www.washington.edu/admin/rules/policies/FCG/FCCH24.html

Every instance that refers to the CAF in the DOP Guidelines for Affiliate Faculty is replaced

with The CHOICE Institute. Additional guidance and procedures specific for The CHOICE Institute to

initiate and support a continued appointment are as follows:

Guidelines for initial appointment – Must meet two or more of the following criteria over

approximately one year:

1. Teaching: Teach at least one lecture in one of the courses offered within The Institute.




Institute.




https://sop.washington.edu/about/office-of-the-dean/clinical-affiliate-faculty/guidelines/




Guidelines for continuation- Must meet two or more of the above criteria over any two

successive academic years.

Process for Initiation to be considered for an Adjunct or Affiliate position:

1. Interested individuals must demonstrate engagement with the Institute in order to meet the

above guideline criteria.

2. A nominating faculty member is responsible for communicating the criteria to the engaged

individual, obtaining their CV, and writing a letter of support describing their current and

future involvement in the Institute

3. The nominating faculty member should present the candidate for consideration at a CHOICE

faculty meeting; materials must be submitted 3 weeks beforehand.

4. Upon agreement at the CHOICE faculty meeting, the nomination will be then presented at a

Department of Pharmacy faculty meeting and subject to DOP faculty vote.

Process for Continuation

1. All Adjunct and Affiliate positions are reviewed annually. Submission materials are submitted

to the CHOICE Graduate Program and Operations Manager by August 31 of each year and

will be reviewed during the Fall quarter.

2. To continue as an Adjunct or Affiliate position for the next academic year, individuals must

write a brief note documenting that they have met the criteria laid out above in any year

over the last two academic years, including the current academic year.



Process for promotion are available at the UW faculty code:


These criteria are also available here:

https://sop.washington.edu/choice/who-we-are/faculty-staff/becoming-adjunct-or-affiliate-faculty/






Jennifer Whiteley EdD, MSc, MA

For nomination at the rank: Affiliate Associate Professor

CONTENTS


NOMINATION LETTER FROM DR. DAVE VEENSTRA ……………………...........…………................ 3

CHOICE ADJUNCT/AFFILIATE FACULTY CRITERIA………………….........………...............………….. 7

1

February 12, 2020

Faculty, Department of Pharmacy University of Washington

RE: Affiliate Faculty nomination for Jennifer Whiteley

Dear Colleagues,

It is my pleasure to nominate Jennifer Whiteley, EdD, MSc, MA, for an Affiliate Associate Professor appointment with the Department of Pharmacy. Dr. Whitely is Head, Neuroscience & Rare Disease in the Evidence for Access group at Genentech and the senior mentor and director of the health economics and outcomes research post-PharmD MS fellowship program our Department has with Genentech. The two fellows in this program complete one year of training and an MS degree with us, followed by a year on-site with Genentech.

Dr. Whiteley received her doctorate from Columbia, where her dissertation topic was “Exploring Medication Adherence in African Americans: What is the Role of Psychosocial Predictors.” She also obtained her MSc in Epidemiology from the London School of Hygiene and Tropical Medicine. She has worked in industry for the past 14 years, and currently holds a senior position directing 11 health economists. A selection of 13 publications are included in her CV.

Dr. Whiteley provides coordination and mentorship in her role as the Genentech HEOR fellowship director. She has quarterly calls with the first-year fellows and coordinates and supervises the industry-side mentors during their first year and helps identify and guide their MS topics. During the second year she has weekly meetings with the fellows, with a high-level focus on professional development and career trajectory.

Dr. Whiteley is an enthusiastic supporter of post-PharmD education. She is highly accomplished and well respected in the HEOR community and would be a great representative of the University of Washington. Dr. Whiteley meets the Affiliate Faculty criteria established for The CHOICE Institute by demonstrating ongoing engagement through student mentorship.

I highly recommend Dr. Whiteley for an Affiliate Faculty position, and propose she be appointed at an Affiliate Associate Professor level given her professional accomplishments and commitment to the Department over the past three years. I look forward to discussing and would be happy to answer any questions.

Sincerely,

David L. Veenstra, PharmD, PhD Professor and Associated Director The Comparative Health Outcomes, Policy & Economics (CHOICE) Institute Department of Pharmacy University of Washington

Jennifer Whiteley EdD, MSc, MA Los Altos, CA | +1 650 534 6150

[email protected]

S U M M A R Y

Experienced pharmaceutical industry leader. Proven record of developing and leading highly effective global Market Access & HEOR teams that generate real-world evidence to demonstrate product value and enable access. Strong strategic agility and expertise in developing evidence and communications to support the launch and reimbursement of products in numerous international markets across multiple therapeutic areas. Expertise includes: real-world data generation, patient centered outcomes, economic models, observational studies and research methodologies. Deep experience with health system assessment models, access and pricing strategies.

P R O F E S S I O N A L E X P E R I E N C E

Head, Neuroscience & Rare Disease Evidence for Access (E4A) Genentech, Inc. | South San Francisco, CA | April 2017 – Present

Enterprise Leader Driving Innovation to Enhance Access and Demonstrate the Value of the Neuroscience and Rare Disease Portfolio

§ Lead strategic development and generation of evidence to support optimal pricing and market access for Neuroscience and Rare Disease Portfolio

§ Co-create collaborative research with key US customers to advance scientific understanding and improve patient outcomes

§ Serve as E4A point of contact to the Neuroscience and Rare Disease squads

§ Ensures team structure and capabilities, strategies and tactics are fully aligned to business needs to generate the greatest possible value for the business

§ Provide servant leadership to a team of 11 health economists; develop next generation of leaders

§ Collaborate internally with leaders across Genentech including Commercial Functions, Government Affairs and Policy, Medical Affairs, Legal teams and Research and Development to define value strategy

§ Oversee research with external research partners and internal analysts to ensure the execution of rigorous, high quality, timely and impactful evidence generation resulting in Health Care Economic Information used by field colleagues for customer interactions

Provide Leadership Internally within Genentech and Externally

§ Defined strategic vision and identified opportunities for co-creation and collaboration with customers including Humana, Aetna and Anthem to support enhanced customer experience

§ Member of Evidence for Access and Spectrum Network Accelerators Leadership teams

§ Support organizational initiatives across Genentech

§ Institute for Clinical & Economic Review (ICER) Emicizumab Review and Siponomid Secondary Progressive MS Review | Led cross-functional teams to proactively engage ICER, and prepared and delivered responses with respect to ICER’s methodological approach to ensure appropriate review of emicizumab and ocrelizumab based on available data; represented Genentech at ICER public meetings

§ Institute for Clinical & Economic Review (ICER) Value Cures Summit. Led engagement with ICER to inform Value Assessment Methods for “Single or Short-Term Transformative Therapies” and represented Genentech at public meeting

§ Director of the Genentech-University of Washington joint HEOR fellowship program

Previous Experience

Senior Medical Science Director Quality of Care, US Medical Affairs (2016-2017)

§ Developed Quality of Care strategies and evidence generation plans to support demonstration of value for products across the Genentech portfolio including Biooncology, Hemlibra and Ocrevus

§ Provided scientific and medical leadership to a team of medical directors

E D U C A T I O N

EdD, Health & Behavior Columbia University Dissertation: “Exploring Medication Adherence in African Americans: What is the Role of Psychosocial Predictors.”

MSc, Epidemiology London School of Hygiene and Tropical Medicine Dissertation: “The World-Wide Distribution of the Beijing/W Strain of Tuberculosis”

MA, Physiology Columbia University Dissertation: “Glut 4 Transport Protein and Non-Insulin Dependent Diabetes.”

BS, Physiology, Cum Laude University of Massachusetts

F E L L O W S H I P S

Centers for Disease Control and Prevention | Epidemiology Fellow

L A N G U A G E S

English | Fluent

S E L E C T E D A W A R D S 2 0 1 8 / 2 0 1 9

Roche Next Award | “Commitment to Patient Access: HEMLIBRA CMS Engagement” OPA Genentech Field Award | Siponimod ICER Review Team

P R O F E S S I O N A L A F F I L I A T I O N S

International Society for Pharmacoeconomics and Outcomes Research | ISPOR Council Member

Senior Director, Global Health & Value Pfizer | New York, NY | January 2010 – March 2016

Led Matrix Team Across Global HEOR & Pricing (2012-2016)

§ Led matrix team in generating innovative global evidence and communication plans to demonstrate the value and support market access for Rare Disease, Oncology, and Inflammation assets

§ Leadership team member providing guidance and recommendations to support strategic planning across the portfolio

§ Accountable for development and alignment of value strategies with business priorities by getting strategic plans approved by various organizational governance bodies

§ Led, managed, conceptualized and implemented HEOR research resulting in publications and FDAMA 114 field tools to communicate the value of Pfizer medicines and support access

§ Engaged with regulatory bodies (FDA, EMA, ODAC) to support clinical development programs

US Health Economics & Outcomes Research: Field Based Managed Care (2010-2012)

§ Accountable for developing and delivering on the US Medical Strategy to enhance customer experience through co-creating solutions to joint challenges aiming to improve patient health and lower costs

§ Built relationships with US payers to identify and develop research collaborations

§ Collaborated with field commercial and medical colleagues to gain alignment and execute on shared goals

§ Developed HEOR vision, strategies and tactics in support of multiple US product launches in Neuroscience and Women’s Health

§ Generated HEOR evidence to demonstrate the clinical and economic differentiation in competitive markets and the timely development of AMCP dossiers, economic models, and real-world evidence to support multiple product launches

§ Designed and presented payer communication materials to key accounts and external stakeholders

Team Leader, Global Health Economics, Outcomes Research and Strategic Pricing Genzyme | Cambridge, MA | August 2008 – May 2010

Team Lead Multiple Sclerosis, Oncology, Rare Disease, Cardiovascular & Biosurgery Business Units

§ Established the global HEOR vision across multiple business units; provided critical input to HEOR strategies and tactics in support of molecules through all phases of drug development ensuring alignment to commercial lifecycle strategy

§ Served on the Medical Leadership teams for Multiple Sclerosis, Oncology, Rare Disease, Biosurgery and Cardiovascular business units, played a critical role in cross-functional planning and decision-making

§ Elevated and demonstrated the value of HEOR and Market Access across the company in support organizational priorities and ensure appropriate staffing alignment to business needs

§ Responsible for the development of global HTA submissions (e.g., UK (NICE), Scotland (SMC), and Korea)

§ Led, managed, conceptualized and implemented HEOR research resulting in publications and FDAMA 114 field tools to communicate the value of Genentech medicines and support access

Associate Director, Global Health Economics and Outcomes Research Pfizer | New York, NY | March 2006 – August 2008

Supported Pipeline, Inline and Global Launch of Multiple Assets Including Diabetes, Obesity, Cardiovascular and Schizophrenia

§ Developed global strategic plans, evidence generation activities and global affiliates training in support of launch for diabetes molecule

§ Responsible for the development of evidence generation strategic plans and tactics for pipeline and in-line molecules

§ Engaged with regulatory bodies (FDA, EMA) to support clinical development programs and regulatory approval

Publications (selected)

Moving Pro Measures from the Promise to Impact in Oncology Clinical Practice: Results from a Systematic Literature Review. Value in Health Oct-Nov 2017 (20): 9, A-452. M Anatchkova, AM Skalicky, J Whiteley, D Jagun, CA McHorney, S Donelson.

Exploring the implementation of patient-reported outcome measures in cancer care: need for more real-world evidence results in the peer reviewed literature. Anatchkova M, Donelson SM, Skalicky AM, McHorney CA, Jagun D, Whiteley J. J Patient Rep Outcomes 2018, 27;2(1): 64.

The Burden of Atopic Dermatitis in U.S. Adults: Results from the 2013 National Health and Wellness Survey. Whiteley J, Emir B, Seitzman R, Makinson G. Curr Med Res Opin 2016 Oct;32(10): 1645-1651.

Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure. Whiteley J, Reisman A, Shapiro M, Cortes J, Cella D. Curr Med Res Opin 2016 Aug;32(8): 1325-34.

The Impact of Menopausal Symptoms on Quality of Life, Productivity, and Economic Outcomes. Whiteley J, DiBonaventura Md, Wagner JS, Alvir J, Shah S. J Womens Health 2013 Nov;22(11):983-90.

Direct and Indirect Costs of Women Diagnosed With Menopause Symptoms. Kleinman NL, Rohrbacker NJ, Bushmakin AG, Whiteley J, Lynch WD, Shah sn. J Occup Environ Med. 2013 Apr;55(4): 465-70.

Treatment Patterns and Prognostic Indicators of Response to Therapy Among Patients With Chronic Myeloid Leukemia in Australia, Canada, and South Korea. Whiteley J, Iyer S, Candrilli SD, Kaye JA. Curr Med Res Opin. 2015;3(2): 299-314.

Real-World Analysis of Tyrosine Kinase Inhibitor Treatment Patterns Among Patients With Chronic Myeloid Leukemia in the United States. Henk HJ, Woloj M, Shaprio M, Whiteley J. Clin Ther. 2015 Jan 1;37(1): 124-33.

Impact of the severity of vasomotor symptoms on health status, resource use, and productivity. Whiteley J, Wagner JS, Bushmakin A, Kopenhafer L, DiBonaventura M, Racketa J. Menopause 2013 May20(5): 518-24.

Impact of co-payment discounts on antidepressant medication adherence and costs. Buikema A, Halpern R, Shah S, Odell K, ALvir J, Hulbert E, Whiteley J. Am J Pharm Benefits. 2015;7(3):136-143

Depression, Quality of Life, Work Productivity, Resource Use, and Costs Among Women Experiencing Menopause and Hot Flashes: A Cross-Sectional Study. DiBonaventura MD, Wagner JS, Alvir J, Whiteley J. Prim Care Companion CNS Disord 2012;14(6).

Health-related quality of life in chronic myeloid leukemia. Trask PC, Cella D, Powell C, Reisman A, Whiteley J, Kelly V. Leuk Res 2013 Jan;37(1):9-13.

Neuropsychological Functioning of Children Treated With Intensive Chemotherapy Followed by Myeloablative Consolidation Chemotherapy and Autologous Hematopoietic Cell Rescue for Newly Diagnosed CNS Tumors: An Analysis of the Head Start II Survivors. Sands SA, Oberg JA, Gardner SL, Whiteley J, Glade-Bender JL. Finlay JL. Pediatr Blood Cancer 2010 Mar;54(3):429-36.







Adjunct Faculty










Institute.



Affiliate Faculty



faculty/guidelines/












Institute.










Amy Tung, PharmD, MS

For nomination at the rank: Affiliate Assistant Professor

CONTENTS


NOMINATION LETTER FROM DR. BETH DEVINE ……………………...........…………..................... 3

CHOICE ADJUNCT/AFFILIATE FACULTY CRITERIA………………….........………...............………….. 8

1

Beth Devine, PhD, PharmD, MBA Professor

Department of Pharmacy Box 357630

Seattle, WA 98195-7630 Tel: 206-221-5760

[email protected]

January 6, 2020 Faculty, Department of Pharmacy and The CHOICE Institute Dear Colleagues: It is with great pleasure that I nominate Dr. Amy Tung for appointment as an Affiliate Assistant Professor in the University of Washington (UW), Department of Pharmacy and within The CHOICE Institute. I have known Dr. Tung since 2012, when she was a PharmD student in the course I coursemaster – Design and Analysis of Medical Studies (PHARM 592). Dr. Tung distinguished herself at that time, seeking to learn research methods, and expressing her interest in managed care, comparative effectiveness research, and health economics and outcomes research (HEOR). Demonstrating her commitment, during her third year in Pharmacy School she served as a research assistant in the Pharmaceutical Outcomes Research and Policy Program (PORPP), assisting faculty and students in conducting databases analyses and building cost-effectiveness models. She next arranged and completed an 8-week APPE at Allergan Pharmaceuticals, and followed shortly thereafter by becoming one of our Allergan Post-PharmD fellows (July 2015-December 2016). Her work was of such high caliber that Allergan invited her to join the firm as a research scientist in the Global Health Economics and Outcomes Research (GHEOR) Department before she completed her fellowship. Since her transition to Allergan, she has provided leadership and mentorship in various capacities to CHOICE graduate students and UW Pharmacy students. In this role, she has assisted fellows in completing their thesis projects and ensuring manuscript publication. In 2018, she became the coordinator of the UW-Allergan fellowship, assuming the role from Dr. Patrick Gillard. She has been a guest speaker at the annual UW-AMCP-Allergan dinner, where she educated pharmacy students on the role of HEOR in industry, and related internship opportunities. She also led development and execution of a nationally-broadcast webinar, hosted by The CHOICE Institute, educating pharmacy students about HEOR industry-sponsored fellowship opportunities. In her leadership role she also co-leads recruitment activities and provides general mentorship to aid current fellows to both maximize and optimize their fellowship experience. She has also worked to improve the operational relationship between The CHOICE faculty and Allergan. With her demonstrated past and current level of involvement in the UW Department of Pharmacy and The CHOICE Institute, and knowing that her commitment and enthusiasm for leadership and mentoring will continue well into the future, I highly recommend Dr. Tung be appointed as an Affiliated Assistant Professor. Thank you for your consideration. Please let me know if I can provide additional information. Very truly yours,

Beth Devine, PhD, PharmD, MBA Professor and Graduate Program Director Adjunct: Health Services, Biomedical Informatics; Member Institute for Public Health Genetics

AMY TUNG, PharmD, MS 8611 Marvale Dr. • Huntington Beach, CA 92646 • 206-660-2922 • [email protected]

A health economics and outcomes researcher with clinical training as a licensed pharmacist. EDUCATION 2015-2016 Masters of Science, Health Economics and Outcomes Research University of Washington, Seattle, WA 2011-2015 Doctor of Pharmacy University of Washington, Seattle, WA 2001-2005 Bachelor of Arts, International Studies University of Washington, Seattle, WA WORK EXPERIENCE Senior Manager July 2018 – Present Allergan, Global Health Economics and Outcomes Research Department; Irvine, CA

• Identify research gaps to determine appropriate health economics and outcomes research strategy and evidence generation plans for products across multiple therapeutic areas (psychiatry, neuroscience, spasticity & movement disorders, and urology)

• Provide strategic and execution oversight of primary & secondary data collection, economic modeling, and patient-reported outcome (PRO) research for products across multiple therapeutic areas

• Collaborate with top thought leaders to develop and manage publication creation, review, approval, submission, and presentation of research in peer-review journals and medical & methodological congresses

• Coordinate University of Washington – Allergan Global Health Economics and Outcomes Research fellowship

Manager January 2017 – July 2018 Allergan, Global Health Economics and Outcomes Research Department; Irvine, CA

• Identify research gaps to determine appropriate health economics and outcomes research strategy and evidence generation plans for products across multiple therapeutic areas (psychiatry and urology)

• Lead execution of primary & secondary data collection, economic modeling, and patient-reported outcome (PRO) research for products across multiple therapeutic areas

• Collaborate with top thought leaders to develop and manage publication creation, review, approval, submission, and presentation of research in peer-review journals and medical & methodological congresses

Fellow July 2015 – December 2016 Year 2: Allergan, Global Health Economics and Outcomes Research Department; Irvine CA

• Key Projects o Conducted analysis of a prospective burden of nocturia study to evaluate the association between

frequency of nocturia episodes and patient-reported outcomes, quality of life, work productivity, healthcare resource utilization, and costs

o Conducted analysis using the Truven Health MarketScan® database to understand the opioid burden among interstitial cystitis patients

o Coordinated with clinical, commercial, and international teams to prepare for the review of LiRIS® at the October 2016 Health Technology Assessment Council Meeting

Year 1: University of Washington, Comparative Health Outcomes, Policy, and Economics Institute; Seattle, WA • Key Projects

o Thesis Title: “Characterizing Healthcare Utilization, Direct Costs, and Comorbidities Associated with Interstitial Cystitis: A Retrospective Claims Analysis.” A Truven Health MarketScan® database analysis.

o Mapped a nocturia-specific quality of life instrument to the EuroQol 5D o Performed a cost-utility analysis to compare a novel immunosuppressive induction agent to the standard

of care in kidney transplants using a decision-tree and a Markov model o Conducted a literature review of long-term adverse events associated with a novel immunosuppressive

induction agent used in kidney transplants

Senior Clinical Writer July 2014 – June 2015 Strategic Pharmacy Innovations, Managed Care Consulting; Seattle, WA

• Analyzed clinical research and published literature to evaluate efficacy and safety of pharmaceutical products • Distilled clinical data into meaningful and accessible information for decision-makers • Wrote dossiers on behalf of pharmaceutical companies to provide an objective and thorough description of their

products Research Assistant January 2013 – September 2013 University of Washington, Pharmaceutical Outcomes Research and Policy Program; Seattle, WA

• Assisted graduate students and faculty to conduct cost-effectiveness research • Extracted and managed Truven Health MarketScan® data in SAS • Assisted in reviewing statistical analysis conducted in STATA

Project Manager March 2007 – September 2009 Management Insight Technologies; Seattle, WA

• Managed a team of analysts and vendors to deliver on high-revenue research studies by providing consistent project delivery, open communication, and unrelenting attention to detail

• Worked with executive and account management teams to design analytical plans to meet clients’ research objectives

• Trained and oversaw junior and senior analysts during all stages of project lifecycle • Led team of project managers to improve company research operations • Streamlined communication with and management of vendors both onshore and offshore to improve project

fluidity • Received 2 promotions within 12 months of being hired as a result of quick learning, execution excellence, and

proven ability to lead Research Manager July 2005 – February 2007 Global Market Insite; Seattle, WA

• Provided day-to-day research consultation to clients in questionnaire design, data collection methodology, sampling strategy and analysis/reporting techniques

• Managed the execution of market research projects by constructing, adapting, and communicating fulfillment plans to geographically- and discipline- diverse teams and outside vendors which include custom developers, programmers, data processors, translation houses, panel managers, reporting analysts, printing companies, and scanning companies

• Onboarded, developed, and streamlined operational process of moving programming tasks to offshore vendor in India

• Managed 25+ accounts through establishing, maintaining, and strengthening client relationships, among these including Google, Microsoft, British Petroleum, and Starz Entertainment

HONORS & AWARDS 2018 Global Health Economics Outcomes Research Biggest Accomplishments – Voted Best Presentation 2018 Global Health Economics Outcomes Research Elevator Pitch – Voted Best Presentation 2017 Global Health Economics Outcomes Research Biggest Accomplishments – Voted Best Presentation 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Poster Presentation Finalist 2016 Higashi Family Pharmaceutical Outcomes Research and Policy Program Graduate Student Fellowship 2015 Lilly Achievement Award: 2015 Dean’s List for Advanced Pharmacy Practice Experience Performance Excellence 2014 Orr Endowed Scholarship

2013 Quick Endowed Scholarship 2013 Rho Chi Honor Society 2012 Top Ten Winner of American Pharmacists Association Local Patient Counseling Competition 2012 Adam Christopher Hansen Endowed Scholarship 2004 Council on International Exchange Education Scholarship PROFESSIONAL AFFILIATIONS & LEADERHIP Healthcare Businesswomen’s Association – Allergan Chapter Board Member 2019-2020 Academy of Managed Care Pharmacy – President 2013-2014 Academy of Managed Care Pharmacy – President-Elect 2012-2013 Rho Chi Honor Society – Initiate University of Washington School of Pharmacy Alumni Association – Board Member 2011-2015 Institute for Healthcare Improvement Open House – Board Member 2011-2012 American Society of Consultant Pharmacists – First Year Liaison 2011-2012 MANUSCRIPTS Citrome L, Jain R, Tung A, Landsman-Blumberg PB, Kramer K, Ali S. Prevalence, treatment patterns, and stay characteristics associated with hospitalizations for major depressive disorder. Journal of affective disorders. 2019; 249:378-384. Dmochowski R, Brucker BM, Cole E, Kawahara D, Pulicharam R, Burk C, Tung A, Hale D. Economic Burden of Illness in Adult Patients with Nocturia. Journal of managed care & specialty pharmacy. 2019; 25(5):593-604. Murray B, Hessami SH, Gultyaev D, Lister J, Dmochowski R, Gillard KK, Stanisic S, Tung A, Boer R, Kaplan S. Cost-effectiveness of overactive bladder treatments: from the US payer perspective. Journal of comparative effectiveness research. 2019; 8(1):61-71. Tung A, Hepp Z, Bansal A, Devine EB. Characterizing Health Care Utilization, Direct Costs, and Comorbidities Associated with Interstitial Cystitis: A Retrospective Claims Analysis. Journal of managed care & specialty pharmacy. 2017; 23(4):474-482. CONFERENCE ABSTACTS & POSTERS

Tung A, Keyloun K, Edwards A, Gillard P. Clinical Events Associated With Increased Healthcare Resource Utilization and Costs Among Patients with Major Depressive Disorder. Academy of Managed Care Pharmacy 2020 Annual Meeting. Houston, TX. April 2020. (Abstract)

Ta J, Sullivan S, Tung A, Oliveri D, Gillard P, Devine B. Healthcare Resource Utilization and Costs Associated with Non-Adherence and Non-Persistence to Antidepressants for Major Depressive Disorder. Academy of Managed Care Pharmacy 2020 Annual Meeting. Houston, TX. April 2020. (Abstract)

Thaliffdeen, R, Tung A, Gillard P, Keyloun K, Higa S. Healthcare Costs of MDD Patients Over Multiple Lines of Therapy and Major Depressive Episodes. Academy of Managed Care Pharmacy 2019 Nexus Meeting. National Harbor, DC. October 2019. (Poster)

Tung A, Wang D, Jennings P, Kramer K, Gillard P. Prevalence and Characteristics of Major Depressive Disorder (MDD)-Related Hospitalizations in Adolescents Diagnosed with MDD. Academy of Managed Care Pharmacy 2019 Annual Meeting. San Diego, CA. March 2019. (Poster)

Tung A, Wang D, Moreira T, Kramer K. Characterizing the Prevalence and Characteristics of Major Depressive Disorder (MDD)-Related Hospitalizations in US Patients Diagnosed with MDD. American Psychiatric Association 2018 Annual Meeting. New York City, NY. May 2018. (Poster)

Brucker B, McVary K, Kawahara S, Pulicharam R, Tung A, Burk C, Dmochowski R. Health-Related Quality of Life (HRQoL) in Patients With Nocturia – Use of a New Nocturia-Specific Patient-Reported Outcome (PRO) Measure. Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2017 Winter Meeting. Scottsdale, AZ. March 2017. (Poster)

Luber K, Kawahara S, Wang D, Tung A, Burk C. The Quality of Life Among Women with Nocturia. American Urogynecologic Society 37th Annual Scientific Meeting. Denver, CO. September 2016 (Poster) Tung A, Hepp Z, Bansal A, Devine B. Characterizing Healthcare Utilization, Direct Costs, and Comorbidities Associated with Interstitial Cystitis: A Retrospective Claims Analysis. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting. Washington DC. May 2016 (Poster) Tung A, Hepp Z, Devine B. The Economic Burden of Interstitial Cystitis in the United States: A Literature Review. UW Corporate Advisory Board Meeting. Seattle, WA. September 2015 (Poster) Tung A, Devine EB, Garrison LP, Estimating the Cost-Utility of Alemtuzumab versus Rabbit Anti-Thymocyte Globulin as Induction Therapy for High-Risk Kidney Transplant Recipients. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 19th Annual International Meeting; Montreal, QC, Canada, June 2014 (Poster). SKILLS Technical: SAS; Stata; SPSS; Microsoft Office Suite; Adobe Photoshop Foreign Languages: English (Native); Mandarin Chinese (Conversational) LICENSES AND CERTIFCATES Active Washington State Pharmacist License [PH60587854] Washington State Department of Health

2013-2014 Biomedical Regulatory Affairs Certificate

University of Washington School of Pharmacy April 2013 Fundamentals of Managed Care Pharmacy Certificate

Academy of Managed Care Pharmacy







Adjunct Faculty










Institute.



Affiliate Faculty



faculty/guidelines/












Institute.







UW Department of Pharmacy Faculty Meeting Agenda...Steve White opens, welcoming everyone to the...

Documents

Transcript of UW Department of Pharmacy Faculty Meeting Agenda...Steve White opens, welcoming everyone to the...